Donepezil Tied to Risk for Overactive Bladder

THURSDAY, Jan. 13, 2022 (HealthDay News) -- There is an increased risk for overactive bladder (OAB) with the cholinesterase inhibitor (ChEI) donepezil versus rivastigmine, according to a study published online Dec. 2 in the Journal of the American Geriatrics Society.
Prajakta P. Masurkar, from the University of Houston in Texas, and colleagues used Medicare claims data (Parts A, B, and D claims dataset from 2013 to 2015) to assess the risk for OAB with individual ChEIs in older adults with dementia. The analysis included 524,975 older adults with dementia who were incident users of ChEIs (80.72 percent used donepezil, 16.41 percent used rivastigmine, and 2.87 percent used galantamine).
The researchers found that overall, OAB diagnosis/antimuscarinic/mirabegron prescription was seen in 5.07 percent of the cohort within six months of ChEI prescription. Donepezil use increased the risk for OAB versus rivastigmine (adjusted hazard ratio, 1.13) when using propensity scores. There was no differential OAB risk between galantamine and rivastigmine.
"The study findings suggest the need to understand and manage medication-related morbidity in older adults with dementia," the authors write.
Abstract/Full Text (subscription or payment may be required)
Related Posts
Los mitos sobre las vacunas contra la COVID provocan bajas tasas de adopción entre los niños de EE. UU.
MARTES, 4 de octubre de 2022 (HealthDay News) -- Casi 8 de cada 10 adultos de...
ACP Creates Living Guideline for Interventions During Acute Phase of Major Depression
THURSDAY, Jan. 26, 2023 (HealthDay News) -- In a living clinical guideline...
Getting a COVID Vaccine Won’t Affect Your Ability to Exercise
TUESDAY, Feb. 8, 2022 (HealthDay News) -- Worried that a COVID-19 vaccine might...
Al adelantar el reloj, aproveche y revise las pilas de las alarmas de humo
VIERNES, 10 de marzo de 2023 (HealthDay News) -- Cuando adelante el reloj para...